Thomas Barwick/DigitalVision via Getty Images Hutchmed logo (Hutchmed) Investment Thesis In our article on HUTCHMED (China) Limited (NASDAQ:HCM) on the 26th of March this year, we continued our Buy stance on the back of our expectations that the company finally is becoming profitable. The share price is up nearly 20%. HCM's colon cancer drug FRUZAQLA's approval by the U.S. FDA at the end of last year was a game-changer for the company with a reported good uptake from U.S. patients after the launch. We belie ...